ARTS-876
/ Allorion Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Preclinical evaluation of ARTS-876, an AKR1C3-activated prodrug targeting KEAP1/NFE2L2-mutant NSCLC
(AACR 2026)
- "Abstract is embargoed at this time."
Late-breaking abstract • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KEAP1 • NFE2L2
1 to 1
Of
1
Go to page
1